Connect Biopharma continues Phase 2 asthma, COPD trials after interim review

April 23, 2026 9:01 AM

Connect Biopharma Holdings Limited (NASDAQ: CNTB) announced that enrollment in its Phase 2 Seabreeze STAT studies will continue as planned ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found